

This form is based on Express Scripts standard criteria and may not be applicable to all patients; certain plans and situations may require additional information beyond what is specifically requested.

Additional forms available: www.express-scripts.com/pa

Fax completed form to **1-877-329-3760**If this an <u>URGENT</u> request, please call 1-800-753-2851

Patient Information	Prescriber Information				
Patient First Name:	Prescriber Name	riber Name:			
Patient Last Name:					
	Prescriber Phone #:				
Patient ID#:					
Patient DOB:	Tresember Address.				
Patient Phone #:					
Primary Diagnosis:	ICD Code:				
<ul> <li>☐ Humira 20mg/0.4ml Syringe (Kit)</li> <li>☐ Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit)</li> <li>☐ Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)</li> </ul>	☐ Humira 40mg/	0.8ml Pen (Kit) 0.8ml Syringe (Kit)			
<ul> <li>☐ Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit)</li> <li>☐ Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)</li> </ul>	□ Humira 40mg/i□ Other	0.8ml Syringe (Kit)			
Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:	□ Humira 40mg/i□ Other	0.8ml Syringe (Kit)			
☐ Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) ☐ Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):	□ Humira 40mg/i□ Other	0.8ml Syringe (Kit)			
Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:	□ Humira 40mg/i□ Other	0.8ml Syringe (Kit)			
Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:  1. Has the patient been established on Humira for greater than or equa	□ Humira 40mg/i□ Other	0.8ml Syringe (Kit)			
□ Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) □ Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:  1. Has the patient been established on Humira for greater than or equa  2. What is the indication or diagnosis? □ Ankylosing spondylitis	☐ Humira 40mg/s ☐ Other	0.8ml Syringe (Kit)	□ No		
☐ Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) ☐ Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:  1. Has the patient been established on Humira for greater than or equa  2. What is the indication or diagnosis? ☐ Ankylosing spondylitis ☐ Behcet's disease ☐ Crohn's disease ☐ Hidradenitis suppurativa	☐ Humira 40mg/s ☐ Other	0.8ml Syringe (Kit)  Pes  Grenosum  thritis in adults	□ No		
□ Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) □ Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:  1. Has the patient been established on Humira for greater than or equa  2. What is the indication or diagnosis? □ Ankylosing spondylitis □ Behcet's disease □ Crohn's disease	☐ Humira 40mg/s ☐ Other	0.8ml Syringe (Kit)  Pes  Grenosum  thritis in adults	□ No		
Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  ections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:  1. Has the patient been established on Humira for greater than or equa  2. What is the indication or diagnosis?  Ankylosing spondylitis Behcet's disease Crohn's disease Crohn's disease Hidradenitis suppurativa Juvenile rheumatoid arthritis (JRA) or Juvenile idiopathic arthritis (JIA)	☐ Humira 40mg/s ☐ Other	O.8ml Syringe (Kit)  Pres  Grenosum  thritis in adults ed spondylarthritis (undiffe	□ No		
Humira 40mg/0.8ml Crohn's Disease Starter Pen (Kit) Humira 40mg/0.8ml Psoriasis Starter Pen (Kit)  Pections for use (i.e. QD, BID, PRN & Qty):  Please complete the clinical assessment:  1. Has the patient been established on Humira for greater than or equa  2. What is the indication or diagnosis?  Ankylosing spondylitis Behcet's disease Crohn's disease Hidradenitis suppurativa Juvenile rheumatoid arthritis (JRA) or Juvenile idiopathic	☐ Humira 40mg/s ☐ Other	O.8ml Syringe (Kit)  Pres  Grenosum  thritis in adults ed spondylarthritis (undiffe	□ No		

3.	Is Hum	nira to be given in combination with any of	the fol	lowing DMARDS:	☐ Yes	□ No	□ N/A
		Actemra (tocilizumab)		Orencia (abatacept)			
		Cimzia (certolizumab pegol)					
		Enbrel (etanercept)		Simponi (golimumab)			
		Kineret (anakinra)		Stelara (ustekinumab)			
		Methotrexate [MTX] (oral, injection)		Xeljanz (tofacitinib)			
		Remicade (infliximab)		Other:			
	Has th	e patient tried one DMARD (brand or gene	ric: ora	Lor injectable) for at least 3 months? If	☐ Yes	□ No	
٠.		ent duration other than 3 months, please sp		Tot injectable, for at least 3 months. If	□ 163		
		Actemra		Orencia			
		Arava (leflunomide)		Plaquenil (hydroxychloroquine)			
		Cimzia		Remicade			
		Enbrel		Rituxan			
		Kineret		Simponi			
		Methotrexate [MTX] (oral, injection)		Sulfasalazine			
		Imuran (azothiaprine)		Other:			
		6-mercaptopurine					
_	Dlassa	list prescriber or consulting prescriber's sp	o cialtu				
5.	Please	ist prescriber or consulting prescriber's sp	eciaity	:			
6.		diagnosis is rheumatoid arthritis in adults,			☐ Yes	□ No	□ N/A
disease duration of less than 6 months) with at least one of the following features of poor prognosis: functional limitation (e.g., based on HAQ-DI score); extraarticular disease such as							
rheumatoid nodules, RA vascultis or Felty's syndrome; positive rheumatoid factor or anti-CCP							
		dies; or bony erosions by radiograph?	, ,				
7. If the diagnosis is Crohn's disease in patients equal to or greater than 6 years of age,		☐ Yes	□ No	□ N/A			
Has the patient tried corticosteroids, or is currently on corticosteroids, or are							
corticosteroids contraindicated in this patient?							
8.	If the	e diagnosis is Crohn's disease, Has the pation	ent had	l ileocolonic resection (to reduce the	☐ Yes	□ No	□ N/A
	chan	ce of Crohn's disease recurrence)?					
9.	If the	diagnosis is Uveitis, has the patient tried o	ne of t	he following therapies: periocular	☐ Yes	□ No	□ N/A
٥.		cular, or systemic corticosteroids, immunos			□ 163		L N/A
mycophenolate mofetil, cyclophosphamide, cyclosporine), Enbrel, or Remicade?							
If yes, please list therapies tried:							
		,, p					
10		e diagnosis is Plaque psoriasis, has the patie			☐ Yes	□ No	□ N/A
		one oral or biologic therapy for plaque psor ane, Enbrel, Remicade, or Stelara)?	asis (e.	.g., methotrexate, cyclosporine,			
						<u> </u>	
11		e diagnosis is Plaque psoriasis, Does the pa			☐ Yes	□ No	□ N/A
	for psoriasis such as methotrexate, as determined by the prescribing physician?						

12. If the diagnosis is Plaque psoriasis, has the pa for 3 months with one of the following:	tient tried a systemic therapy or phototherapy	☐ Yes	□ No	□ N/A
If yes, please indicate:				
<ul> <li>□ Acitretin (Soriatane)</li> <li>□ Cyclosporine</li> <li>□ Etanercept (Enbrel)</li> <li>□ Infliximab (Remicade)</li> </ul>	<ul> <li>□ Methotrexate</li> <li>□ Oral methoxsalen with ultraviolet A light (PUVA)</li> <li>□ Ustekinumab (Stelara)</li> <li>□ Other:</li></ul>			
13. If the diagnosis is Ulcerative colitis, has the pa (e.g., 6-mercaptopurine, azathioprine, cyclosposuch as prednisone or methylprednisolone) or ulcerative colitis?  If yes, please list:	orine, tacrolimus, Remicade, or a corticosteroid	□ Yes	□ No	□ N/A
14. If the diagnosis is Ulcerative colitis, does the pan antibiotic (e.g., metronidazole, ciprofloxacin (mesalamine) enema?  If yes, please list:	), probiotic, corticosteroid enema, or Rowasa	□ Yes	□ No	□ N/A
15. If the diagnosis is Juvenile rheumatoid arthrit tried one other agent for this condition (e.g., m biologic DMARD (e.g., Enbrel, Orencia, Remicae starting on Humira concurrently with methotre	ethotrexate, sulfasalazine, or leflunomide or a de, Kineret, Actemra), or an NSAID, or will be xate, sulfasalazine, or leflunomide?	□ Yes	□ No	□ N/A
16. If the diagnosis is Juvenile rheumatoid arthrit have an absolute contraindication to methotre alcoholic liver disease, immunodeficiency synd leflunomide?  If no, does the patient have aggressive physician?  Yes	xate (for example: pregnancy, breast feeding,	□ Yes	□ No	□ N/A
condition?	as the patient tried one other therapy (for systemic antibiotics, isotretinoin) for the current	□ Yes	□ No	□ N/A
18. If the diagnosis is Pyoderma gangrenosum, Find therapy (for example: systemic corticosteroid methotrexate, mycophenolate mofetil, tacrol cyclosporine], interferon alfa), Enbrel, or Remission (Fig. 1).	s, immunosuppressants [azathioprine, imus, Leukeran, cyclophosphamide,	☐ Yes	□ No	□ N/A

example: s mycophen	<u>diagnosis is Behcet's disease</u> , has the patient tried at least one conventional therapy (for ole: systemic corticosteroids, immunosuppressants [azathioprine, methotrexate, ohenolate mofetil, tacrolimus, Leukeran, cyclophosphamide, cyclosporine], interferon Enbrel, or Remicade?		□ No	□ N/A
If yes, plea	se list:			
	Are there any other comments, diagnoses, symptoms, and/or any ot physician feels is important to this review?			
	iber Signature:Phone Number:	_Date:		

Based upon each patient's prescription plan, additional questions may be required to complete the prior authorization process. If you have any questions about the process or required information, please contact our prior authorization team at the number listed on the top of this form.

Prior Authorization of Benefits is not the practice of medicine or a substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for the patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions.

The document(s) accompanying this transmission may contain confidential health information. This information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you received this information in error, please notify the sender immediately and arrange for the return or destruction of the documents.